Peter Greenleaf Insider Trading $ATRS ANTARES PHARMA, INC.
Get free email notifications about insider trading for Peter Greenleaf.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter Greenleaf. Peter Greenleaf is Senior VP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales & Marketing in MEDIMMUNE INC /DE ($MEDI) and SVP, Sales and Marketing in MEDIMMUNE INC /DE ($MEDI) and Director in ANTARES PHARMA, INC. ($ATRS) and Director in BIODELIVERY SCIENCES INTERNATIONAL INC ($BDSI) and Director in Mast Therapeutics, Inc. ($MSTX) and CEO in Sucampo Pharmaceuticals, Inc. ($SCMP) and Chief Executive Officer in Sucampo Pharmaceuticals, Inc. ($SCMP) and Director in EYEGATE PHARMACEUTICALS INC ($EYEG) and Director in Mirna Therapeutics, Inc. ($MIRN) and in Cerecor Inc. ($CERC) and Chief Executive Officer in Cerecor Inc. ($CERC) and Director in Cerecor Inc. ($CERC) and Chief Executive Officer in Aurinia Pharmaceuticals Inc. ($AUPH).
Peter Greenleaf in ANTARES PHARMA, INC.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of Peter Greenleaf: Director
Holdings: 54,193 shares
Current Value: $119,225
Latest Transaction: Jun 15 2020
$ATRS Market Capitalization: $356.70M
$ATRS Previous Close: $2.20
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Peter Greenleaf in ANTARES PHARMA, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATRS, AUPH, BDSI, CERC, EYEG, MEDI, SVRA, SCMP, SYBX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.92 | 23,973 | 70,001 | 23,973 | 0 to 24 K |
| Dec 14 2018 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 3.11 | 20,000 | 62,200 | 20,000 |
Page: 1